Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Nektar Therapeutics Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$94.9 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 14, 2024	SELL	$0.9 - $1.83 $91,124 - $185,285	-101,249 Reduced 35.08%	187,385 $232,000
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $184,725 - $909,197	288,634 New	288,634 $202,000

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.5 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$13.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$11.9 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.55 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.37 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account